Clinical trials: Advanced RCC
Carcinoma, Renal Cell
Study Evaluating Renal Cell Carcinoma Risk Factors
This is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell…
- Trial name
- MICRA (NCT00927043)
- Testing
- Epidemiological study according to clinical practice
- Where
- Spain
- Volunteers
- 145 people
- Sponsor
- Pfizer
Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma
A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma
This is a multicenter, single-arm, phase 2 clinical trial designed to evaluate the clinical efficacy of combination therapy with zanzalintinib and pembrolizumab in patients with locally advanced intermediate- to high-risk…
- Trial name
- NCT07691476
- Testing
- Zanzalintinib and Pembrolizumab
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT01131234
- Testing
- Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
Study of Intermittent OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
- Trial name
- NCT00514306
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Astellas Pharma Inc
Carcinoma, Renal Cell
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.
- Trial name
- NCT02454478
- Testing
- Lenvatinib, Everolimus
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Eisai Co., Ltd.
Renal Cell Carcinoma
CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma
This is a phase I, open-label, single-arm study conducted to evaluate the safety, tolerability, PK, and preliminary efficacy of CGC729 with Relapsed or Metastatic advanced renal cell carcinoma.
- Trial name
- NCT06182735
- Testing
- Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Fudan University
Renal Cell Carcinoma
Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma
Temsirolimus is a drug that is being studied to possibly treat kidney cancer. It works by starving the cancer of nutrients, by cutting off the blood supply, which is hoping to shrink the cancer.
- Trial name
- NCT01404104
- Testing
- Temsirolimus (pre surgery)
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Immune Checkpoint Inhibitors-induced Colitis, Advanced Melanoma Skin Cancer, Non-small Cell Lung Carcinoma, Kidney Adenocarcinoma
Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis
This is a multicentric, observational study, including all European centres willing to take part. The multicentre nature is necessary for enhancing the generalisability of our results, and due to the rarity of this condition.
- Conditions
- Immune Checkpoint Inhibitors-induced Colitis, Advanced Melanoma Skin Cancer, Non-small Cell Lung Carcinoma, Kidney Adenocarcinoma, Ileo-colitis, Immune Mediated-colitis
- Trial name
- NCT06899789
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Metastatic Renal Cell Carcinoma
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
SUNNIFORECAST (Standard of Care vs. Nivolumab + Ipilimumab as First line treatment of renal cell cancer of non-clear cell subtypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab…
- Trial name
- NCT03075423
- Testing
- Ipilimumab plus nivolumab, Standard Therapy
- Where
- 30 sites in Belgium, Czechia and 5 more
- Volunteers
- 316 people
- Sponsor
- Goethe University
Papillary Renal Cell Carcinoma
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally…
- Trial name
- PRCC (NCT07024680)
- Testing
- Observational, None intervention
- Where
- China
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
This phase I/II trial studies the side effects of sitravatinib and how well it works with nivolumab in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT03015740
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
The purpose of the protocol, is to describe the use of cabozantinib tablets as monotherapy or in combination with nivolumab including the number of dose reductions, dose interruptions and terminations due to (serious) adverse…
- Trial name
- CABOCARE (NCT03647878)
- Where
- 82 sites in Austria, Germany
- Volunteers
- 224 people
- Sponsor
- Ipsen
Metastatic Clear Cell Renal Cell Carcinoma
Radiopharmaceutical Treatment of Advanced Kidney Cancer
Background This study is for adults with advanced kidney cancer that has spread to other parts of the body and has continued to progress despite treatment with immunotherapy and targeted therapy.
- Trial name
- RENALUT (NCT06783348)
- Testing
- 177Lu-PSMA-617
- Where
- 2 sites in France
- Volunteers
- 48 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Renal Cell Carcinoma
IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients
This is a monocenter, single-arm, prospective phase Ib trial, designed to evaluate the safety, clinical toxicity and in vivo immunological effects of a patient-individualized peptide vaccination added to standard of care…
- Trial name
- NCT05641545
- Testing
- IVAC
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- SLK Kliniken Heilbronn GmbH
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Kidney Cancer Stage Iv, Advanced Melanoma
Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma
This is a phase Ib, open, mono-center, dose-escalation, tolerability and pharmacokinetic study evaluating the Recombinant Humanized Anti-PD-1 mAb for Injection in combination with Axitinib in patients with advanced kidney cancer…
- Trial name
- NCT03086174
- Testing
- humanized anti-PD-1 monoclonal antibody Toripalimab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Renal Cell Cancer, Kidney Cancer
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
The goal of this clinical research study is to learn the effectiveness of Sutent® (sunitinib malate, SU011248) in the treatment of patients with non-clear cell renal cell cancer.
- Trial name
- NCT00465179
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003342
- Testing
- filgrastim, carboplatin, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics